Investor Relations

INSPIRA™ ART100

Blood Oxygenation

The INSPIRA™ ART100 is an advanced extracorporeal blood oxygenation device, designed for Cardio-Pulmonary Bypass. It will feature the HYLA™ 1 Blood Sensor, seamlessly integrated into the system to provide real-time blood monitoring, enhancing patient outcomes during critical procedures.

Certifications and Approvals

The INSPIRA™ ART100 system has received FDA clearance under the 510(k) regulations and holds AMAR approval from the Israeli Ministry of Health.

Gen 2

INSPIRA™ ART500

Adaptive Blood Oxygenation

The INSPIRA™ ART500 system introduces a new standard in respiratory care by offering a less invasive alternative to mechanical ventilation, allowing patients to remain awake and comfortable. Equipped with the VORTX™ Orbital Blood Oxygenation technology and the HYLA™ Blood Sensor, it will ensure continuous monitoring and real-time detection of changes in a patient’s condition, providing vital decision-making support to clinicians. This innovative approach aims to improve outcomes in both ICU and non-ICU settings, making it a versatile solution for various healthcare environments.

Market Opportunity

$1 Billion

Perfusion Systems Market

$19 Billion

Mechanical Ventilation Market

Schedule a meeting

For a one-on-one update on inspira’s activities, schedule a
meeting with Joe Hayon, President and Co-founder

Download Investor deck

Latest News and Press Releases

March 26, 2026

Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates

February 18, 2026

Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State

View all

SEC Filings Research Coverage Corporate Governance

Firm

Analyst

E-mail

Diamond Equity Research

Hunter Diamond, CFA

[email protected]

Litchfield Hills Research LLC

Theodore R. O’Neill

[email protected]

Inspira Technologies is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Inspira Technologies’ performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Inspira Technologies or its management. Inspira Technologies does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Charter of the compensation committee of the board of directors

Insider trading policy and guidelines with respect to certain transactions in company securities

Charter of the audit committee of the board of directors

Employee complaint procedures for accounting and auditing matters